Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride

Meulyzer, M.; Vachon, Pascal; Beaudry, Francis; Vinardell, Tatiana; Richard, Hélène; Beauchamp, Guy

doi:10.1016/j.joca.2008.06.018

Cited by 27 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that supplemental glucosamine reaches the site of action, i.e., the joints and the synovial fluid [6][7][8][9][10][11]. Supplemental glucosamine can therefore be utilised by the cells to maintain the balance between the breakdown and synthesis in the form of dietary supplements).…”

Section: The Role Of Glucosamine In Joint Physiologymentioning

confidence: 99%

Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?

Bernhardt

Jaenicke

Prock³

et al. 2015

Nutrafoods

View full text Add to dashboard Cite

Section: The Role Of Glucosamine In Joint Physiologymentioning

confidence: 99%

Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?

Bernhardt

Jaenicke

Prock³

et al. 2015

Nutrafoods

View full text Add to dashboard Cite

“…The applicant also provided studies in animals on the effect of glucosamine on cartilage formation/degradation (Chen et al, 2010;Meulyzer et al, 2009;Naito et al, 2010;Oegema et al, 2002;Taniguchi et al, 2012). Four studies were provided in animal models of OA, i.e.…”

Section: Mechanistic Studiesmentioning

confidence: 99%

“…in rats and rabbits with OA induced surgically or enzymatically (Chen et al, 2010;Naito et al, 2010;Oegema et al, 2002) and in Hartley guinea pigs susceptible to spontaneous OA (Taniguchi et al, 2012). One study was provided on the effect of glucosamine on induced (by injection of lipopolysaccharides from E. coli) inflammation of joints in horses (Meulyzer et al, 2009). The applicant was invited to justify the validity of the animal models in the context of the claimed effect, i.e.…”

Section: Mechanistic Studiesmentioning

confidence: 99%

Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joint cartilage pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Publication¹

2012

EFSA Journal

View full text Add to dashboard Cite

Following an application from Merck Consumer Healthcare, submitted pursuant to Article 13(5) of Regulation (EC) via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to glucosamine, formulated as glucosamine sulphate or hydrochloride, and maintenance of normal joint cartilage. Glucosamine is sufficiently characterised. The claimed effect is "contributes to the maintenance of normal joint cartilage". The target population as proposed by the applicant is the general population, and in particular people exposing their joints to high mechanical load and people with joint cartilage deterioration due to normal ageing. The Panel considers that the maintenance of normal joint cartilage is a beneficial physiological effect. The applicant provided references to studies in patients with osteoarthritis, in healthy subjects, in animals and in vitro as being pertinent to the health claim. In weighing the evidence, the Panel took into account that no human studies were provided from which conclusions could be drawn on the effect of dietary glucosamine on the maintenance of cartilage in individuals without osteoarthritis, and that the evidence provided in the in vitro and animal studies in support of the biological plausibility for a possible contribution of dietary glucosamine to the maintenance of joint cartilage in humans is weak. The Panel concludes that a cause and effect relationship has not been established between the consumption of glucosamine and maintenance of normal joint cartilage in individuals without osteoarthritis. © European Food Safety Authority, 2012 The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. KEY WORDSThe food constituent that is the subject of the health claim is glucosamine, formulated as glucosamine sulphate or hydrochloride. The Panel considers that glucosamine is sufficiently characterised.The claimed effect is "contributes to the maintenance of normal joint cartilage". The target population as proposed by the applicant is the general population, and in particular people exposing their joints to high mechanical load, for example through extensive sports activities or obesity, and people with joint cartilage deterioration due to normal ageing. From the information provided, the Panel notes that the claimed effect relates to the maintenance of joint cartilage. The Panel considers that the maintenance of normal joint cartilage is a beneficial physiological effect.In the original application, the applicant identified a total of 61 references as being pertinent to the health claim. These references comprised 20 references describing 12 human intervention studies, 13 reviews on the effects of glucosamine supplementation on maintenance of joints, four animal studies on the effects of glucosamine on joints, 14 in vitro studies on the effects of glucosamine on cartilage cells/tissues, nine studies i...

show abstract

“…Chapter inflammation based in these studies will likely be in the range of 1-18 µM for both horses and humans and most in vitro studies showing benefits with glucosamine used considerably higher concentrations (Meulyzer et al 2009). in vitro studies to the in vivo situation by providing some prediction of fluid and tissue concentrations for GU and CS after oral dosing.…”

mentioning

confidence: 99%

“…The conclusion was that higher synovial fluid concentrations of glucosamine were achieved with glucosamine sulfate, but whether this difference translated into a therapeutic effect on the joint tissues remains to be elucidated (Meulyzer et al 2008). In a follow-up paper the same research group demonstrated that joint inflammation (induced with Escherichia coli lipopolysaccharide [LPS]) increases GU levels obtained in synovial fluid following oral administration of glucosamine hydrochloride up to fourfold higher than in the clinically normal joints suggested the possibility of an enhanced effect (as synovitis is important in the pathobiology of equine OA) (Meulyzer et al 2009). On the other hand, the maximal GU levels attainable in the synovial fluid in the presence of…”

mentioning

confidence: 99%

Oral joint supplements in the management of osteoarthritis

McIlwraith¹

2013

Equine Applied and Clinical Nutrition

View full text Add to dashboard Cite

Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride

Cited by 27 publications

References 30 publications

Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?

Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?

Scientific Opinion on the substantiation of a health claim related to glucosamine and maintenance of normal joint cartilage pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Oral joint supplements in the management of osteoarthritis

Contact Info

Product

Resources

About